Mycosis Fungoides Overview
Learn About Mycosis Fungoides
Mycosis fungoides is the most common form of a type of blood cancer called cutaneous T-cell lymphoma. Cutaneous T-cell lymphomas occur when certain white blood cells, called T cells, become cancerous; these cancers characteristically affect the skin, causing different types of skin lesions. Although the skin is involved, the skin cells themselves are not cancerous. Mycosis fungoides usually occurs in adults over age 50, although affected children have been identified.
The cause of mycosis fungoides is unknown. Most affected individuals have one or more chromosomal abnormalities, such as the loss or gain of genetic material. These abnormalities occur during a person's lifetime and are found only in the DNA of cancerous cells. Abnormalities have been found on most chromosomes, but some regions are more commonly affected than others. People with this condition tend to have additions of DNA in regions of chromosomes 7 and 17 or loss of DNA from regions of chromosomes 9 and 10. It is unclear whether these genetic changes play a role in mycosis fungoides, although the tendency to acquire chromosome abnormalities (chromosomal instability) is a feature of many cancers. It can lead to genetic changes that allow cells to grow and divide uncontrollably.
Mycosis fungoides occurs in about 1 in 100,000 to 350,000 individuals. It accounts for approximately 70 percent of cutaneous T-cell lymphomas. For unknown reasons, mycosis fungoides affects males nearly twice as often as females. In the United States, there are an estimated 3.6 cases per million people each year. The condition has been found in regions around the world.
The inheritance pattern of mycosis fungoides has not been determined. Although the condition has been found in multiple members of more than a dozen families, it most often occurs in people with no history of the disorder in their family and is typically not inherited.
City Of Hope Medical Foundation
Christiane Querfeld is a Dermatologist in Newport Beach, California. Dr. Querfeld and is rated as an Elite provider by MediFind in the treatment of Mycosis Fungoides. Her top areas of expertise are Mycosis Fungoides, Cutaneous T-Cell Lymphoma (CTCL), T-Cell Lymphoma, and Sezary Syndrome.
Jefferson University Physicians
Pierluigi Porcu is an Oncologist and a Hematologist Oncology provider in Philadelphia, Pennsylvania. Dr. Porcu and is rated as an Elite provider by MediFind in the treatment of Mycosis Fungoides. Their top areas of expertise are T-Cell Lymphoma, Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides, Bone Marrow Transplant, and Bone Marrow Aspiration.
City Of Hope Medical Foundation
Jasmine Zain is a Hematologist and a Hematologist Oncology provider in Newport Beach, California. Dr. Zain and is rated as an Elite provider by MediFind in the treatment of Mycosis Fungoides. Her top areas of expertise are T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Cutaneous T-Cell Lymphoma (CTCL), Bone Marrow Transplant, and Bone Marrow Aspiration.
Summary: The purpose of this study is to test any good and bad effects of the study drug called brentuximab vedotin at a lower dose than is FDA-approved.
Summary: The researchers are doing this study to test the safety of combining bexarotene with TSEB radiotherapy in people who have a common form of CTCL called mycosis fungoides (MF). Bexarotene is a form of vitamin A that activates proteins called retinoid X receptors, which may stop the growth of cancer cells and kill them. TSEB radiotherapy is a type of radiation therapy that treats the entire surface o...
Published Date: May 17, 2021
Published By: National Institutes of Health